MET and ovarian adenocarcinoma: Alternative explanations for the observed MET overexpression could be gene amplification, as reported in non-small-cell lung carcinoma [19] and in ovarian adenocarcinoma [20], gains of 7q (MET gene is located on 7q31) that are known to be involved in the progression of insulinomas and other pNETs [21], and epigenetic modifications, such as loss of DNA methylation, already identified in a mouse model of hepatocellular carcinoma [22].